𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Feasibility of anti-VEGF agent bevacizumab in patients with Crohn's disease

✍ Scribed by Romain Coriat; Olivier Mir; Sarah Leblanc; Stanislas Ropert; Catherine Brezault; Stanislas Chaussade; François Goldwasser

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
42 KB
Volume
17
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adalimumab safety in global clinical tri
Adalimumab safety in global clinical trials of patients with Crohn's disease
✍ Jean-Frédéric Colombel; William J. Sandborn; Remo Panaccione; Anne M. Robinson; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB 👁 2 views

Background: Adalimumab, a fully human anti-tumor necrosis factor (anti-TNF) monoclonal antibody, is approved for the treatment of Crohn's disease (CD) in adults. We evaluated the overall safety profile of adalimumab in global clinical trials in patients with CD. Patients who participated in these tr

Further experience with the use of 6-thi
Further experience with the use of 6-thioguanine in patients with Crohn's disease
✍ Azhar Ansari; Tim Elliott; Farina Fong; Monica Arenas-Hernandez; Giles Rottenber 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

Background: 6-Thioguanine (6-TG) is efficacious in patients with Crohn's Disease (CD) failing conventional immunosuppression but there are reports of hepatotoxicity. We report our experience of the safety and efficacy of 6-TG in a series of patients with CD. Methods: A retrospective study of patien